2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1222

Incidence and Time Trends of Malignancy in Rheumatoid Arthritis: A Population Based Study 1980-2007
Abstract Number: 1974

Incidence of Atypical Femur Fractures Associated with Bisphosphonate Use for Osteoporosis: A Systematic Review of the Literature
Abstract Number: 1487

Incidence of Fibromyalgia Syndrome in Systemic Sclerosis and Rheumatoid Arthritis. Comparative Results According to Clinical Diagnosis, Screening Test with Fibromyalgia Rapid Screening Tool, Diagnosis with ACR1990 and ACR 2010 Criteria
Abstract Number: 915

Incidence of Knee, Hip, and Hand Clinical Osteoarthritis: A Population-Based Cohort Study
Abstract Number: 253

Incidence of Osteoarthritis-Related Knee and Hip Joint Surgery in Southern Sweden
Abstract Number: 763

Incidence of Selected Opportunistic Infections Among Children with Juvenile Idiopathic Arthritis
Abstract Number: 940

Incidence of Systemic Lupus Erythematosus in England, 1998-2010
Abstract Number: 654

Incidence Studies of Systemic Lupus Erythematosus in Southern Sweden. Have the Tides Turned
Abstract Number: 250

Incident and Worsening Cartilage Damage in the Lateral Compartment and Multiple Subregions Worsening in the Medial Compartment Increase the Risk for Knee Replacement – Data From the Osteoarthritis Initiative
Abstract Number: 2468

Incident Symptomatic Hip Osteoarthritis Is Associated with Differences in Hip Shape by Active Shape Modeling: The Johnston County Osteoarthritis Project
Abstract Number: 2355

Increase in Duration and Cumulative Dose of Glucocorticoid Therapy in Recent Decades: Observations From a Population-Based Cohort of Patients with Giant Cell Arteritis
Abstract Number: 1710

Increase in Vitamin D Improves Disease Activity and Systolic Blood Pressure in Systemic Lupus Erythematosus
Abstract Number: 2329

Increase of CD4⁺CD25⁺FoxP₃⁺ T Cell in Patients with Systemic Sclerosis Could Secret IL-17 with Dysfunction of Immunosuppression
Abstract Number: 1905

Increase of Thyroid Stimulating Hormone in Patients On Febuxostat Treatment
Abstract Number: 1681

Increased Arterial Stiffness in Juvenile Idiopathic Arthritis (JIA) Patients Compared with Matched Controls – a Pilot Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].